Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.

Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.

Publication date: Oct 06, 2019

The microbiome is increasingly recognized for its role in multiple aspects of cancer development and treatment, specifically in response to checkpoint inhibitors. While checkpoint inhibitors have revolutionized cancer treatment by producing durable anti-tumor responses, only a minority of patients respond to the available immunotherapy drugs and accurate, sensitive and specific microbiome predictors of response to treatment remain elusive. Additionally, the specific mechanisms linking the microbiome and host immunological responses remain unclear. In this review, we examine the evidence for the gut microbiome’s association with anti-tumor responses to checkpoint inhibitors in the treatment of melanoma, non-small cell lung cancer, and renal cell carcinoma. Furthermore, we discuss the current evidence available from murine models seeking to explain the immunological mechanisms that may drive this process. While this work is promising in defining the impact of gut microbiota in cancer treatment, many unanswered questions indicate the need for additional human and experimental studies.

Open Access PDF

Shaikh, F.Y., Gills, J.J., and Sears, C.L. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. 24423. 2019 EBioMedicine.

Concepts Keywords
Gut Microbiota Immunotherapy
Immunotherapy Melanoma
Lung Immune system
Lung Cancer Checkpoint inhibitor
Melanoma Bacteriology
Microbiome Microbiology
Murine RTT
Renal Carcinoma Cancer treatments
Tumor Branches of biology
Clinical medicine
Medicine
Immunotherapy
Durable anti tumor

Semantics

Type Source Name
disease MESH Infection
disease MESH immunocompromised patients
gene UNIPROT ATIC
gene UNIPROT MBNL1
disease DOID hepatocellular carcinoma
disease MESH hepatocellular carcinoma
disease MESH Metastasis
gene UNIPROT TOX
gene UNIPROT MENT
drug DRUGBANK Trestolone
gene UNIPROT APC
disease MESH dysbiosis
gene UNIPROT NSMAF
gene UNIPROT SLC7A5
gene UNIPROT ELK3
gene UNIPROT EPHB1
gene UNIPROT SLC6A2
drug DRUGBANK Troleandomycin
disease MESH lung diseases
gene UNIPROT TFPI
gene UNIPROT CEBPA
gene UNIPROT KCTD11
gene UNIPROT REN
gene UNIPROT CPOX
disease MESH Metabolic syndrome
gene UNIPROT SET
disease MESH microsatellite instability
gene UNIPROT SCN8A
gene UNIPROT EXOG
disease MESH sepsis
disease DOID ess
gene UNIPROT EMD
gene UNIPROT NFKBIZ
gene UNIPROT FURIN
gene UNIPROT CRB2
disease MESH communities
disease DOID renal carcinoma
disease DOID lung cancer
disease MESH lung cancer
drug DRUGBANK Coenzyme M
gene UNIPROT IMPACT
pathway BSID Non-small cell lung cancer
disease DOID non-small cell lung cancer
disease MESH non-small cell lung cancer
gene UNIPROT S100A6
drug DRUGBANK N N-dimethylglycine
gene UNIPROT SNAP25
gene UNIPROT API5
drug DRUGBANK Methylergometrine
gene UNIPROT FOXP3
gene UNIPROT CXCL10
gene UNIPROT CXCL9
gene UNIPROT NELFCD
gene UNIPROT CCR9
gene UNIPROT CXCR3
disease MESH tumorigenesis
gene UNIPROT IL17A
gene UNIPROT ITGAX
drug DRUGBANK Esomeprazole
gene UNIPROT ITGAM
gene UNIPROT PTPRC
gene UNIPROT MTFMT
gene UNIPROT CD4
gene UNIPROT USP9X
gene UNIPROT MS4A2
disease DOID colitis
disease MESH colitis
gene UNIPROT LUM
disease MESH autoimmunity
gene UNIPROT GOPC
gene UNIPROT TP53
gene UNIPROT KRAS
drug DRUGBANK Platinum
drug DRUGBANK Cisplatin
gene UNIPROT CTLA4
gene UNIPROT PDCD1
gene UNIPROT SPATA2
drug DRUGBANK Nivolumab
gene UNIPROT TRIM37
disease DOID carcinoma
disease MESH carcinoma
gene UNIPROT AATF
disease MESH lung adenocarcinomas
gene UNIPROT FAM155B
disease MESH recurrence
disease MESH inflammation
disease DOID squamous carcinoma
drug DRUGBANK Enterococcus faecium
gene UNIPROT RNH1
disease MESH death
pathway BSID Renal cell carcinoma
disease MESH renal cell carcinoma
disease DOID renal cell carcinoma
disease MESH development
disease DOID cancer
disease MESH cancer
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
disease MESH squamous carcinoma
disease MESH smokers
gene UNIPROT PUF60
gene UNIPROT FARP2
gene UNIPROT PARP9
gene UNIPROT SLC27A5
drug DRUGBANK Dimercaprol
gene UNIPROT CEL
pathway BSID Fatty acids
gene UNIPROT MUC1
drug DRUGBANK Ipilimumab
drug DRUGBANK Indoleacetic acid
gene UNIPROT CCAR1
gene UNIPROT TBPL1
drug DRUGBANK Piroxicam
gene UNIPROT ATP12A
gene UNIPROT ATP4A
drug DRUGBANK Metformin
gene UNIPROT PLXNA3
pathway BSID Immune System

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *